U.S. License Holder:
Amgen Inc.
Date of License:
May-17-2018
Last Update:
Sep-30-2024
FDA-Approved Indications
AIMOVIG (erenumab-aooe) is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.